FDA clears AstraZeneca breast cancer drug

The US Food and Drug Administration has granted accelerated approval to AstraZeneca’s (AZN) breast cancer medicine camizestrant. The decision, dated September 4, 2026, allows the drug to enter the US market under a pathway intended to speed access to therapies for serious diseases where there is an unmet medical need.

Camizestrant is an oral breast cancer pill and represents a regulatory milestone for AstraZeneca in oncology. The approval marks a key step in bringing a new targeted option to patients with advanced disease driven by specific genetic features.

The authorization covers adults with estrogen receptor 1 (ESR1)-mutated, hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. This defines a genetically driven subset of metastatic breast cancer in which ESR1 mutations play a role in disease biology and treatment resistance.

By limiting use to ESR1‑mutated HR+, HER2‑ disease, the label targets patients whose tumors meet specific molecular criteria. Clinicians will need to identify eligible patients based on the presence of ESR1 mutations and the hormonal and HER2 status of the cancer.

Under the approval, camizestrant can be prescribed in combination with CDK4/6 inhibitors abemaciclib, palbociclib, or ribociclib. These medicines are widely used targeted therapies in HR+ metastatic breast cancer and act on cell cycle regulation.

The ability to combine camizestrant with these CDK4/6 inhibitors positions the drug as part of a coordinated treatment approach. Using the new agent alongside established targeted therapies could allow physicians to align treatment with both molecular drivers and standard-of-care regimens.

The accelerated US approval gives AstraZeneca an additional asset in its breast cancer portfolio focused on genetically defined disease. The decision strengthens the company’s position in HR+ metastatic breast cancer, an area where targeted and combination regimens are central to care.

As an accelerated approval, the authorization underscores regulatory recognition of the need for new options in serious oncologic conditions. Camizestrant’s entry to the US market in this setting may influence future development and treatment strategies for ESR1‑mutated metastatic breast cancer.